Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
LeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

ArriVent BioPharma (AVBP) Leases (2023 - 2026)

ArriVent BioPharma has reported Leases over the past 4 years, most recently at $370000.0 for Q1 2026.

  • Quarterly results put Leases at $370000.0 for Q1 2026, up 208.33% from a year ago — trailing twelve months through Mar 2026 was $370000.0 (up 208.33% YoY), and the annual figure for FY2025 was $13000.0, down 91.56%.
  • Leases reached $370000.0 in Q1 2026 per AVBP's latest filing, up from $13000.0 in the prior quarter.
  • Across five years, Leases topped out at $370000.0 in Q1 2026 and bottomed at $13000.0 in Q4 2025.
  • Median Leases over the past 4 years was $170500.0 (2024), compared with a mean of $173800.0.
  • The largest annual shift saw Leases plummeted 91.56% in 2025 before it surged 208.33% in 2026.
  • Over 4 years, Leases stood at $291000.0 in 2023, then crashed by 47.08% to $154000.0 in 2024, then tumbled by 91.56% to $13000.0 in 2025, then skyrocketed by 2746.15% to $370000.0 in 2026.
  • Business Quant data shows Leases for AVBP at $370000.0 in Q1 2026, $13000.0 in Q4 2025, and $49000.0 in Q3 2025.